Cara Therapeutics | CARA - Debt


Cara Therapeutics reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Cara Therapeutics USD 0 0 Mar/2025
Cassava Sciences USD 0 0 Dec/2024
Chugai Pharma JPY 14.11B 1.93B Dec/2022
Cipla INR 6.14B 1.76B Mar/2026
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.93M 14K Mar/2026
CSL USD 11.96B 219M Dec/2024
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 63.19B 536M Jun/2026
RedHill Biopharma USD 214K 142K Jun/2025
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024